Premium
Survival benefits with the addition of adjuvant hysterectomy to radiochemotherapy for treatment of stage I‐II adenocarcinoma of the uterine cervix
Author(s) -
Huang XiaoBin,
Zhang WenWen,
Wu SanGang,
Sun JiaYuan,
He ZhenYu,
Zhou Juan
Publication year - 2018
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.25153
Subject(s) - medicine , hazard ratio , stage (stratigraphy) , propensity score matching , hysterectomy , adjuvant , adenocarcinoma , cervix , gynecology , cervical cancer , oncology , survival rate , surgery , cancer , confidence interval , paleontology , biology
Background and Objectives: To determine the survival benefits of additional adjuvant hysterectomy in the International Federation of Gynecology and Obstetrics (FIGO) stage I‐II cervical adenocarcinoma patients treated with radiochemotherapy. Methods: Patients with FIGO stage I‐II cervical adenocarcinoma were selected from the Surveillance, Epidemiology, and End Results 18 Regs research database. Propensity score matching (PSM) was used to balance patient baseline characteristics. Patient characteristics and outcomes were compared between the two groups. Results: A total of 530 patients were included, 389 (73.4%) underwent definitive radiochemotherapy and 141 (26.6%) underwent an additional adjuvant hysterectomy. The multivariate Cox analysis surgery was shown to be an independent predictor of survival. Before PSM, the hazard ratios for cause‐specific survival and overall survival in the surgery group were 0.632 ( P = 0.036) and 0.674 ( P = 0.041), respectively. After PSM, the respective hazard ratios were 0.392 ( P < 0.001) and 0.465 ( P = 0.001). The surgery group had significantly better 5‐year cause‐specific survival (80.5% vs 59.1%; P = 0.001) and overall survival than the nonsurgery group (76.3% vs 56.0%; P = 0.002). Conclusions: Additional adjuvant hysterectomy after radiochemotherapy may improve survival outcomes in patients with FIGO stage I‐II cervical adenocarcinoma.